Lukas Hainz

Imagine a world where a single treatment could manage type 2 diabetes or obesity for months at a time, freeing patients from the burden of daily medications and the frustrating cycle of weight regain. This isn’t a distant dream but a potential reality being shaped by Junevity, a biotechnology

Imagine a world where living to 100 is common, yet the decline of mind and body feels just as relentless as it does today—where longer life doesn’t mean slower aging. This paradox lies at the heart of a provocative critique by Dr. Dan Ehninger and Dr. Maryam Keshavarz, published in Genomic

Imagine a world where the trial-and-error nature of drug discovery is replaced by a precise, predictive system capable of designing therapies for some of humanity’s most stubborn diseases. This vision is no longer a distant dream but a tangible goal for insitro, a South San Francisco-based AI

Imagine a world where the most stubborn cancers, those that defy conventional treatments, can be halted not by destroying cells but by coaxing them into a state of permanent rest. This vision is inching closer to reality with a pioneering technology that harnesses the power of machine learning to

Diving into the intricate world of molecular biology and neurodegenerative disease research, I’m thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with a wealth of experience in research and development. His innovative work has pushed boundaries in understanding the complex

Imagine a world where the intricate dance of molecules within the brain can be captured in stunning detail, offering a roadmap to tackle one of neurology’s most persistent challenges—epilepsy. This vision is becoming reality thanks to cryo-electron microscopy (Cryo-EM), a cutting-edge technology

Diving into the complex world of microbiome research, I had the privilege of speaking with Ivan Kairatov, a renowned biopharma expert with extensive experience in technology and innovation within the industry. With a strong background in research and development, Ivan has been instrumental in

Ivan Kairatov has spent years at the crossroads of oncology and drug development, translating trial signals into day-to-day decisions for patients with localized prostate cancer. In this conversation, he unpacks new evidence showing that most of the value from androgen deprivation therapy (ADT)

Imagine a world where a lung cancer diagnosis no longer feels like a death sentence, but rather a challenge that can be managed with the right tools and support. For too long, this disease has carried a heavy burden of fear and stigma, often seen as an unstoppable force due to its high mortality

Watching a single enzyme switch from a standstill to full sprint while decoding DNA inside a mammalian cell would have sounded like science fiction not long ago, yet that leap just became a measurable reality thanks to a single-molecule transcription platform that links factor binding to RNA